Pharmaceutical company Slayback Pharma LLC reported on Wednesday the receipt of final approval from the US Food and Drug Administration (FDA) for its ANDA for Icatibant Injection 30 mg/3 ml (10 mg/ml) in a Prefilled Syringe for treating acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.
Icatibant Injection is the generic equivalent of Firazyr.
Angioedema (which can include swelling of the throat or larynx) can be life-threatening. HAE is an inherited condition characterized by recurrent episodes of nonpruritic, nonpitting, subcutaneous or submucosal swelling without the presence of urticarial lesions. Multiple areas of the body can be involved including hands, feet, intestinal wall, genitalia, face, tongue or larynx. Swelling of the pharynx or larynx can be life-threatening due to asphyxia.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling